Liver metastases of neuroendocrine tumours; early reduction of tumour load to improve life expectancy

World Journal of Surgical Oncology

Volumn 4, Issue , 2006, Pages

  Veenendaal, Liesbeth M ^a   Borel Rinkes, Inne H M ^a   Lips, Cornelis J M ^a   van Hillegersberg, Richard ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 131; ALPHA INTERFERON; CHROMOGRANIN A; DOXORUBICIN; METHOTREXATE; OCTREOTIDE; SEROTONIN; SOMATOSTATIN RECEPTOR;

ALGORITHM; ARTIFICIAL EMBOLISM; CANCER ADJUVANT THERAPY; CARCINOID SYNDROME; CLINICAL TRIAL; CYTOREDUCTIVE SURGERY; DIAGNOSTIC VALUE; DISEASE COURSE; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; FOLLOW UP; HUMAN; HYPERTHERMIC THERAPY; LIFE EXPECTANCY; LIVER FAILURE; LIVER METASTASIS; LIVER TRANSPLANTATION; NEUROENDOCRINE TUMOR; PARTIAL HEPATECTOMY; QUALITY OF LIFE; RADIOFREQUENCY ABLATION; REVIEW; SPIRAL COMPUTER ASSISTED TOMOGRAPHY; SYSTEMIC THERAPY; THERMOCOAGULATION; TUMOR SCINTISCANNING; UNSPECIFIED SIDE EFFECT;

EID: 33746702549     PISSN: 14777819     EISSN: 14777819     Source Type: Journal    
DOI: 10.1186/1477-7819-4-35     Document Type: Review

References (67)

1. Rindi G, Bordi C: Highlights of the biology of endocrine tumours of the gut and pancreas. Endocr Relat Cancer 2003, 10:427-436.
2. Williams ED, Sandler M: The classification of carcinoid tumours. Lancet 1963, 1:238-239.
3. Solcia E, Kloppel G, Sobbin LH: Histological typing of endocrine tumours. In International histological classification of endocrine tumours Springer-Verlag: New York: 2000.
4. Benevento A, Boni L, Frediani L, Ferrari A, Dionigi R: Result of liver resection as treatment for metastases from noncolorectal cancer. J Surg Oncol 2000, 74:24-29.
5. Godwin JD: Carcinoid tumors. An analysis of 2,837 cases. Cancer 1975, 36:560-569.
6. McDermott EW, Guduric B, Brennan MF: Prognostic variables in patients with gastrointestinal carcinoid tumours. Br J Surg 1994, 81:1007-1009.
7. Zeitels J, Naunheim K, Kaplan EL, Straus F: Carcinoid tumors: a 37-year experience. Arch Surg 1982, 117:732-737.
8. Oates JA: The carcinoid syndrome. N Engl J Med 315:702-704. 11-9-1986
9. Chamberlain RS, Canes D, Brown KT, Saltz L, Jarnagin W, Fong Y, Blumgart LH: Hepatic neuroendocrine metastases: does intervention alter outcomes? J Am Coll Surg 2000, 190:432-445.
10. Chen H, Hardacre JM, Uzar A, Cameron JL, Choti MA: Isolated liver metastases from neuroendocrine tumors: does resection prolong survival? J Am Coll Surg 1998, 187:88-92.
11. Farthing MJ: 5-Hydroxytryptamine and 5-hydroxytryptamine-3 receptor antagonists. Scand J Gastroenterol Suppl 1991, 188:92-100.
12. Kema IP, de Vries EG, Slooff MJ, Biesma B, Muskiet FA: Serotonin, catecholamines, histamine, and their metabolites in urine, platelets, and tumor tissue of patients with carcinoid tumors. Clin Chem 1994, 40:86-95.
13. Meijer WG, Kema IP, Volmer M, Willemse PH, de Vries EG: Discriminating capacity of indole markers in the diagnosis of carcinoid tumors. Clin Chem 2000, 46:1588-1596.
14. Carling RS, Degg TJ, Allen KR, Bax ND, Barth JH: Evaluation of whole blood serotonin and plasma and urine 5-hydroxyindole acetic acid in diagnosis of carcinoid disease. Ann Clin Biochem 2002, 39:577-582.
15. Kema IP, Schellings AM, Meiborg G, Hoppenbrouwers CJ, Muskiet FA: Influence of a serotonin- and dopamine-rich diet on platelet serotonin content and urinary excretion of biogenic amines and their metabolites. Clin Chem 1992, 38:1730-1736.
16. Bajetta E, Ferrari L, Martinetti A, Celio L, Procopio G, Artale S, Zilembo N, Di Bartolomeo M, Seregni E, Bombardieri E: Chromogranin A, neuron specific enolase, carcinoembryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors. Cancer 86:858-865. 1-9-1999
17. Hutton JC, Davidson HW, Peshavaria M: Proteolytic processing of chromogranin A in purified insulin granules. Formation of a 20 kDa N-terminal fragment (betagranin) by the concerted action of a Ca2+-dependent endopeptidase and carboxypeptidase H (EC 3.4.17.10). Biochem J 244:457-464. 1-6-1987
18. Pirker RA, Pont J, Pohnl R, Schutz W, Griesmacher A, Muller MM: Usefulness of chromogranin A as a marker for detection of relapses of carcinoid tumours. Clin Chem Lab Med 1998, 36:837-840.
19. Nobels FR, Kwekkeboom DJ, Coopmans W, Schoenmakers CH, Lindemans J, De Herder WW, Krenning EP, Bouillon R, Lamberts SW: Chromogranin A as serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the alpha-subunit of glycoprotein hormones. J Clin Endocrinol Metab 1997, 82:2622-2628.
20. Gibril F, Reynolds JC, Doppman JL, Chen CC, Venzon DJ, Termanini B, Weber HC, Stewart CA, Jensen RT: Somatostatin receptor scintigraphy: its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomas. A prospective study. Ann Intern Med 125:26-34. 1-7-1996
21. Chiti A, Fanti S, Savelli G, Romeo A, Bellanova B, Rodari M, van Graafeiland BJ, Monetti N, Bombardieri E: Comparison of somatostatin receptor imaging, computed tomography and ultrasound in the clinical management of neuroendocrine gastro-entero-pancreatic tumours. Eur J Nud Med 1998, 25:1396-1403.
22. Frucht H, Doppman JL, Norton JA, Miller DL, Dwyer AJ, Frank JA, Vinayek R, Maton PN, Jensen RT: Gastrinomas: comparison of MR imaging with CT, angiography, and US. Radiology 1989, 171:713-717.
23. Termanini B, Gibril F, Reynolds JC, Doppman JL, Chen CC, Stewart CA, Sutliff VE, Jensen RT: Value of somatostatin receptor scintigraphy: a prospective study in gastrinoma of its effect on clinical management. Gastroenterology 1997, 112:335-347.
24. Panzuto F, Falconi M, Nasoni S, Angeletti S, Moretti A, Bezzi M, Gualdi G, Polettini E, Sciuto R, Festa A, Scopinaro F, Corleto VD, Bordi C, Pederzoli P, Delle FG: Staging of digestive endocrine tumours using helical computed tomography and somatostatin receptor scintigraphy. Ann Oncol 2003, 14:586-591.
25. Kwekkeboom DJ, Krenning EP, Bakker WH, Oei HY, Kooij PP, Lamberts SW: Somatostatin analogue scintigraphy in carcinoid tumours. Eur J Nucl Med 1993, 20:283-292.
26. Que FG, Sarmiento JM, Nagorney DM: Hepatic surgery for metastatic gastrointestinal neuroendocrine tumors. Cancer Control 2002, 9:67-79.
27. Liu LX, Zhang WH, Jiang HC: Current treatment for liver metastases from colorectal cancer. World J Gastroenterol 2003, 9:193-200.
28. Wong SL, Edwards MJ, Chao C, Simpson D, McMasters KM: Radiofrequency ablation for unresectable hepatic tumors. Am J Surg 2001, 182:552-557.
29. Berber E, Flesher N, Siperstein AE: Laparoscopic radiofrequency ablation of neuroendocrine liver metastases. World J Surg 2002, 26:985-990.
30. Hellman P, Ladjevardi S, Skogseid B, Akerstrom G, Elvin A: radiofrequency tissue ablation using cooled tip for liver metastases of endocrine tumors. World J Surg, 2002, 26:1052-1056.
31. Wessels FJ, Schell SR: Radiofrequency ablation treatment of refractory carcinoid hepatic metastases. J Surg Res 2001, 95:8-12.
32. Siperstein AE, Rogers SJ, Hansen PD, Gitomirsky A: Laparoscopic thermal ablation of hepatic neuroendocrine tumor metastases. Surgery 1997, 122:1147-1154.
33. Meij V, Zuetenhorst JM, van Hillegersberg R, Kroger R, Prevoo W, van Coevorden F, Taal BG: Local treatment in unresectable hepatic metastases of carcinoid tumors: Experiences with hepatic artery embolization and radiofrequency ablation. World J Surg Oncol 2005, 3:75.
34. de Baere T, Elias D, Dromain C, Din MG, Kuoch V, Ducreux M, Boige V, Lassau N, Marteau V, Lasser P, Roche A: Radiofrequency ablation of 100 hepatic metastases with a mean follow-up of more than 1 year. AJR Am J Roentgenol 2000, 175:1619-1625.
35. Veenendaal LM, de Jager A, Stapper G, Borel Rinkes IHM, van Hillegersberg R: Multiple fiber laser-induced thermotherapy for ablation of large intrahepatic tumors. Photomed Laser Surg 2006, 24:3-9.
36. Veenendaal LM, Borel Rinkes IHM, van Hillegersberg R: Multipolar radiofrequency ablation of large hepatic metastases of endocrine tumours. Eur J Gastroenterol Hepatol 2006, 18:89-92.
37. Henn AR, Levine EA, McNulty W, Zagoria RJ: Percutaneous radiofrequency ablation of hepatic metastases for symptomatic relief of neuroendocrine syndromes. AJR Am J Roentgenol 2003, 181:1005-1010.
38. Curley SA, Marra P, Beaty K, Ellis LM, Vauthey JN, Abdalla EK, Scaife C, Raut C, Wolff R, Choi H, Loyer E, Vallone P, Fiore F, Scordino F, De RV, Orlando R, Pignata S, Daniele B, Izzo F: Early and late complications after radiofrequency ablation of malignant liver tumors in 608 patients. Ann Surg 2004, 239:450-458.
39. Poon RT, Ng KK, Lam CM, Ai V, Yuen J, Fan ST, Wong J: Learning curve for radiofrequency ablation of liver tumors: prospective analysis of initial 100 patients in a tertiary institution. Ann Surg 2004, 239:441-449.
40. Wettstein M, Vogt C, Cohnen M, Brill N, Kurz AK, Modder U, Haussinger D: Serotonin release during percutaneous radiofrequency ablation in a patient with symptomatic liver metastases of a neuroendocrine tumor. Hepatogastroenterology 2004, 51:830-832.
41. Warner RR, Mani S, Profeta J, Grunstein E: Octreotide treatment of carcinoid hypertensive crisis. Mt Sinai J Med 1994, 61:349-355.
42. Veall GR, Peacock JE, Bax ND, Reilly CS: Review of the anaesthetic management of 21 patients undergoing laparotomy for carcinoid syndrome. Br J Anaesth 1994, 72:335-341.
43. Kinney MA, Warner ME, Nagorney DM, Rubin J, Schroeder DR, Maxson PM, Warner MA: Perianaesthetic risks and outcomes of abdominal surgery for metastatic carcinoid tumours. Br J Anaesth 2001, 87:447-452.
44. Roche A: [Hepatic chemo-embolization]. Bull Cancer 1989, 76:1029-1037.
45. Schell SR, Camp ER, Caridi JG, Hawkins IF Jr: Hepatic artery embolization for control of symptoms, octreotide requirements, and tumor progression in metastatic carcinoid tumors. J Gastrointest Surg 2002, 6:664-670.
46. Carrasco CH, Charnsangavej C, Ajani J, Samaan NA, Richli W, Wallace S: The carcinoid syndrome: palliation by hepatic artery embolization. AJR Am J Roentgenol 1986, 147:149-154.
47. Diamandidou E, Ajani JA, Yang DJ, Chuang VP, Brown CA, Carrasco HC, Lawrence DD, Wallace S: Two-phase study of hepatic artery vascular occlusion with microencapsulated cisplatin in patients with liver metastases from neuroendocrine tumors. AJR Am J Roentgenol 1998, 170:339-344.
48. O'Toole D, Maire F, Ruszniewski P: Ablative therapies for liver metastases of digestive endocrine tumours. Endocr Relat Cancer 2003, 10:463-468.
49. Kress O, Wagner HJ, Wied M, Klose KJ, Arnold R, Alfke H: Transarterial chemoembolization of advanced liver metastases of neuroendocrine tumors - a retrospective single-center analysis. Digestion 2003, 68:94-101.
50. Kolmannskog F, Kolbenstvedt AN, Schrumpf E, Hanssen LE: Side effects and complications after hepatic artery embolization in the carcinoid syndrome. Scand J Gastroenterol 1991, 26:557-562.
51. Brown KT, Koh BY, Brody LA, Getrajdman GI, Susman J, Fong Y, Blumgart LH: Particle embolization of hepatic neuroendocrine metastases for control of pain and hormonal symptoms. J Vasc Interv Radiol 1999, 10:397-403.
52. Oberg K: Endocrine tumors of the gastrointestinal tract: systemic treatment. Anticancer Drugs 1994, 5:503-519.
53. Jacobsen MB, Hanssen LE: Clinical effects of octreotide compared to placebo in patients with gastrointestinal neuroendocrine tumours. Report on a double-blind, randomized trial. J Intern Med 1995, 237:269-275.
54. Prvulovich EM, Stein RC, Bomanji JB, Ledermann JA, Taylor I, Ell PJ: Iodine-131-MIBG therapy of a patient with carcinoid liver metastases. J Nucl Med 1998, 39:1743-1745.
55. Safford SD, Coleman RE, Gockerman JP, Moore J, Feldman J, Onaitis MW, Tyler DS, Olson JA Jr: Iodine-131 metaiodobenzylguanidine treatment for metastatic carcinold. Cancer 101:1987-1993. 28-9-2004
56. Oberg K, Eriksson B: The role of interferons in the management of carcinoid tumours. Br J Haematol 1991, 79(Suppl 1):74-77.
57. Faiss S, Pape UF, Bohmig M, Dorffel Y, Mansmann U, Golder W, Riecken EO, Wiedenmann B. Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors - the International Lanreotide and Interferon Alfa Study Group. J Clin Oncol 21:2689-2696. 15-7-2003
58. Pape UF, Wiedenmann B: Adding interferon-alpha to octreotide slows tumour progression compared with octreotide alone but evidence is lacking for improved survival in people with disseminated midgut carcinoid tumours. Cancer Treat Rev 2003, 29:565-569.
59. Schally AV, Nagy A: Cancer chemotherapy based on targeting of cytotoxic peptide conjugates to their receptors on tumors. Eur J Endocrinol 1999, 141:1-14.
60. Nagy A, Schally AV: Targeted cytotoxic somatostatin analogs: a modern approach to the therapy of various cancers. Drugs Future 2001, 26:261-270.
61. De Jong M, Valkema R, Jamar F, Kvols LK, Kwekkeboom DJ, Breeman WA, Bakker WH, Smith C, Pauwels S, Krenning EP. Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings. Semin Nucl Med 2002, 32:133-140.
62. Lam MG, Lips CJ, Jager PL, Dullaart RP, Lentjes EG, van Rijk PP, de Klerk JM: Repeated [1311]metaiodobenzylguanidine therapy in two patients with malignant pheochromocytoma. J Clin Endocrinol Metab 2005, 90:5888-5895.
63. Florman S, Toure B, Kim L, Gondolesi G, Roayaie S, Krieger N, Fishbein T, Emre S, Miller C, Schwartz M: Liver transplantation for neuroendocrine tumors. J Gastrointest Surg 2004, 8:208-212.
64. Penn I: Hepatic transplantation for primary and metastatic cancers of the liver. Surgery 1991, 110:726-734.
65. Le Treut YP, Delpero JR, Dousset B, Cherqui D, Segol P, Mantion G, Hannoun L, Benhamou G, Launois B, Boillot O, Domergue J, Bismuth H: Results of liver transplantation in the treatment of metastatic neuroendocrine tumors. A 31-case French multicentric report. Ann Surg 1997, 225:355-364.
66. Lehnert T: Liver transplantation for metastatic neuroendocrine carcinoma: an analysis of 103 patients. Transplantation 66:1307-1312. 27-11-1998
67. Ahlman H, Friman S, Cablin C, Nilsson O, Jansson S, Wangberg B, Olausson M: Liver transplantation for treatment of metastatic neuroendocrine tumors. Ann N Y Acad Sci 2004, 1014:265-269.